NCT03622008View on ClinicalTrials.gov

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

May 13, 2018

Study Completion Date

May 30, 2018

Conditions

Antibiotics Causing Adverse Effects in Therapeutic Use

Interventions

DRUG

FEP-TAZ 4 g

FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days

OTHER

Placebo

Placebo IV

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Clinartis, LLC

UNKNOWN

lead

Wockhardt

INDUSTRY